Allarity Therapeutics, Inc. Preferred Stock Dividends, Income Statement Impact
Allarity Therapeutics, Inc. (ALLR) reported Preferred Stock Dividends, Income Statement Impact of $228.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2024-08-05
- Allarity Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2024-03-31 was $228.00K, a 5600.00% increase year-over-year.
- Allarity Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-12-31 was $0.00.
- Allarity Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-09-30 was $0.00.
- Allarity Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2023-06-30 was $119.00K.
- Allarity Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2023 was $123.00K, a 92.18% decline from fiscal 2022.
- Allarity Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2022 was $1.57M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2024-03-31 | $228.00K 10-Q · filed 2024-05-14 | $228.00K derived: sum of 2 quarters · filed 2024-05-14 | $228.00K derived: sum of 3 quarters · filed 2024-05-14 | $347.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $119.00K derived: sum of 3 quarters · filed 2024-08-05 | $123.00K 10-K · filed 2024-03-08 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $119.00K derived: sum of 2 quarters · filed 2024-08-05 | $123.00K 10-Q · filed 2023-11-14 | $123.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-06-30 | $119.00K 10-Q · filed 2024-08-05 | $123.00K 10-Q · filed 2024-08-05 | $123.00K derived: sum of 3 quarters · filed 2024-08-05 | $123.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $4.00K 10-Q · filed 2023-05-11 | $4.00K derived: sum of 2 quarters · filed 2024-03-08 | $4.00K derived: sum of 3 quarters · filed 2024-03-08 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $1.57M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.57M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $1.57M 10-Q · filed 2022-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |